Literature DB >> 16980297

Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function.

Ian R Watson1, Alvaro Blanch, Dan C C Lin, Michael Ohh, Meredith S Irwin.   

Abstract

Mutations in p73 are rare in cancer. Emerging evidence suggests that the relative expression of various p73 isoforms may contribute to tumorigenesis. Alternative promoters and N-terminal splicing result in the transcription and processing of either full-length (TA) or N-terminally truncated (deltaN) p73 isoforms. TAp73 possesses pro-apoptotic functions, while deltaNp73 has anti-apoptotic properties via functional inhibition of TAp73 and p53. Here, we report that TAp73, but not deltaNp73, is covalently modified by NEDD8 under physiologic conditions in an Mdm2-dependent manner. Co-expression of NEDP1, a cysteine protease that specifically cleaves NEDD8 conjugates, was shown to deneddylate TAp73. In addition, blockage of the endogenous NEDD8 pathway increased TAp73-mediated transactivation of p53- and p73-responsive promoter-driven reporter activity, and in conjunction, neddylated TAp73 species were found preferentially in the cytoplasm. These results suggest that Mdm2 attenuates TAp73 transactivation function, at least in part, by promoting NEDD8-dependent TAp73 cytoplasmic localization and provide the first evidence of a covalent post-translational modification exclusively targeting the TA isoforms of p73.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980297     DOI: 10.1074/jbc.M603654200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy.

Authors:  Tomoaki Tanaka; Tatsuya Nakatani; Tetsu Kamitani
Journal:  Mol Oncol       Date:  2012-01-21       Impact factor: 6.603

Review 2.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

3.  Ribosomal proteins are targets for the NEDD8 pathway.

Authors:  Dimitris P Xirodimas; Anders Sundqvist; Akihiro Nakamura; Linnan Shen; Catherine Botting; Ronald T Hay
Journal:  EMBO Rep       Date:  2008-02-15       Impact factor: 8.807

4.  Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation.

Authors:  Sarah Burge; Daniel P Teufel; Fiona M Townsley; Stefan M V Freund; Mark Bycroft; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

Review 5.  Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series.

Authors:  Gwénaël Rabut; Matthias Peter
Journal:  EMBO Rep       Date:  2008-09-19       Impact factor: 8.807

6.  Mdm2 and MdmX as Regulators of Gene Expression.

Authors:  Lynn Biderman; James L Manley; Carol Prives
Journal:  Genes Cancer       Date:  2012-03

7.  Recognition and cleavage of related to ubiquitin 1 (Rub1) and Rub1-ubiquitin chains by components of the ubiquitin-proteasome system.

Authors:  Rajesh K Singh; Sylvia Zerath; Oded Kleifeld; Martin Scheffner; Michael H Glickman; David Fushman
Journal:  Mol Cell Proteomics       Date:  2012-10-26       Impact factor: 5.911

8.  NEDDylation regulates E2F-1-dependent transcription.

Authors:  Sarah J Loftus; Geng Liu; Simon M Carr; Shonagh Munro; Nicholas B La Thangue
Journal:  EMBO Rep       Date:  2012-07-27       Impact factor: 8.807

Review 9.  Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.

Authors:  Yongchao Zhao; Meredith A Morgan; Yi Sun
Journal:  Antioxid Redox Signal       Date:  2014-02-20       Impact factor: 8.401

10.  NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation.

Authors:  T Hosono; T Tanaka; K Tanji; T Nakatani; T Kamitani
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.